NIH unit awards vaccine contract to Crucell

10/5/2008 | Boston Globe (tiered subscription model), The

Crucell announced that it secured a contract worth as much as $70 million from the National Institute of Allergy and Infectious Diseases to develop vaccines for the Ebola and Marburg viruses, which are responsible for hemorrhagic fever. The Dutch biotech firm said it will work with the Southwest Foundation for Biomedical Research in San Antonio and Quintiles Guy's Drug Research Unit in London for the project.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX